Moogene Medi's revenue has long consisted mainly of research services and sample sales. According to aggregator data, revenue was roughly KRW 7 million in 2021, KRW 20 million in 2022, KRW 140.03 million in 2023 and KRW 116.52 million in 2024.
Revenue in 2025 reached KRW 1.41 billion, up 1,110% year on year, although the drivers of the increase are only partly disclosed. The 2025 operating loss of KRW 1.58 billion was narrower than the KRW 2.92 billion loss recorded in 2024.
The operating margin improved to -112.32% from -2,504.61% in 2024, but costs remain large relative to sales. The 2025 net loss of KRW 1.47 billion was smaller than the KRW 6.23 billion loss in 2024. At the end of 2025, total equity stood at about KRW 2.54 billion against total liabilities of about KRW 7.11 billion.
In December 2025 the company signed a co-development agreement for its male-pattern hair-loss drug with Yuhan, JW Pharmaceutical and Medicakorea, with the contract value undisclosed.
On March 12, 2026 the company decided on a KRW 5 billion convertible bond placed privately with Yuhan, with a conversion price of 2,620 KRW. On March 13, 2026 it decided on a third-party rights offering of about KRW 1.1 billion, with proceeds used to repay loans from individual lenders.
The share price fell from 2,795 KRW on March 31, 2026 to 1,850 KRW at the current quote on November 11, 2026. The all-time low of 1,350 KRW was recorded on July 3, 2024.